retatrutide clinical trials sign up phase approval: FDA status, trial results, and when it could be available Do not obsess over Retatrutide Retatrutide for Weight Loss: TRIUMPH-1

Potential to Treat Liver Diseases (NAFLD/NASH): Retatrutide is also being investigated for its potential benefits in treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), which are associated with metabolic disorders

The funder was involved in the following aspects: study design, data analysis and their interpretation, decision to submit for publication, general indications and overview in the writing of this article

Tirzepatide, the dual GIP/GLP-1 agonist, has shown even greater efficacy in the SURMOUNT trials, with patients losing up to 22.5% of body weight

RhrbornDBrcknerJSellHEckelJ